(Accepted for publication July 16, 2021. Published online first on September 8, 2021.)

An Updated Minimal Clinically Important Difference for the QoR-15 Scale

To the Editor:

e have previously reported the minimal clinically important difference for three quality of recovery (QoR) scales. The minimal clinically important difference describes the smallest change in score that constitutes a meaningful change in health status—in our case, this pertains to QoR after surgery. We had estimated the minimal clinically important difference of the QoR-15 using an average (triangulation) of three distribution-based methods (0.3 SD, standard error of the measurement, and 5% range), and a standard anchor-based method,^{2,3} resulting in an minimal clinically important difference of 8.0.1 Distribution-based methods are based on the statistical variability of assessment scales, accounting for measurement error. The anchor-based method uses repeat patient ratings that quantify the extent of change (i.e., improvement or deterioration) of health status over time.^{2,4–7} This method calibrates ("anchors") the change in health status—here quality of recovery measured by the QoR-15 scale—as perceived by patients relative to their previous state.

We have had an ongoing concern that our original estimation of minimal clinically important difference for the QoR-15 scale (minimal clinically important difference = 8.0) was too high. This is in part because of the discrepancy between the three distribution (mean minimal clinically important difference = 5.7) and anchor-based (minimal clinically important difference = 13) estimates in our original report¹ and experience in measuring patient outcomes after surgery in a recent large clinical trial evaluating dexamethasone in which patients reported less postoperative nausea and vomiting and less acute pain at rest.8 This concern is further heightened when considering previous estimations of the responsiveness of the QoR-15, 9,10 which indicate very high ability to detect real change. There are several shortcomings of anchor-based methods, including that anchor questions used to establish minimal clinically important difference are rarely validated and are susceptible to recall bias¹¹ and will be affected by outliers. We have therefore undertaken further analysis.

An additional method of determining the minimal clinically important difference is to use receiver operating

characteristic curve analysis. 12,13 A receiver operating characteristic curve plots the trade-off between the sensitivity and specificity of a binary diagnostic test, in this case correctly identifying whether minimal improvement (or greater) in QoR has occurred, according to change in QoR-15 score. We defined "minimal improvement" as a change from +1 to +2 or more (more than 1 point) on the 15-point Likert scale used in the original anchor-based method. The area under the receiver operating characteristics curve (AUC) would equal 1 where a test has both perfect sensitivity and specificity, and an AUC of 0.5 represents discrimination that is no better than chance. When used for estimation of minimal clinically important difference, sensitivity is defined as the proportion of patients who report improvement based on the external criterion and have a patient-reported outcome—here at least minimal improvement in the QoR-15 score. The minimal clinically important difference is the point on the receiver operating characteristic curve that achieves the optimal trade-off between sensitivity and specificity, and the Youden index (maximal sensitivity + specificity - 1) provides an index of the improvement in sensitivity above chance at this point.¹⁴

Using this approach on the original dataset, we found that the AUC was 0.83 (95% CI: 0.74 to 0.91), P < 0.001 (see fig. 1), indicating excellent discrimination. A change in QoR-15 score of both 3.5 and 4.5 yielded the highest sensitivity (0.765 and 0.735, respectively) and specificity (0.758 and 0.788, respectively), resulting in a Youden's index of 0.52.




Fig. 1. The receiver operating characteristic curve (ROC) depicting sensitivity and specificity of a change in the QoR-15 score to predict minimal improvement in quality of recovery after surgery.

If we now include the average of these values (4.0) in the previous averaged estimate using distribution and anchorbased methods,¹ the pooled mean minimal clinically important difference for the QoR-15 becomes 6.8 (median 5.7). However, given the consistency across distribution and ROC methods, we therefore recommend that the minimal clinically important difference for the QoR-15 scale be updated to a value of 6.0. We hope this can better guide sample size calculations for clinical trials and assist clinicians to interpret results of clinical studies.

Competing Interests

Dr. Paul S. Myles led the development and original validation of the QoR scales. Dr. Paul S. Myles is supported by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship, Canberra, Australia. Mr. Daniel B. Myles is supported by the Australian Government Research Training Program, New South Wales Department of Health, Office of Responsible Gambling, Sydney, Australia. The authors declare no other competing interests.

Paul S. Myles, M.P.H., M.D., D.Sc., Daniel B. Myles, B.A., G.Dip.Psych., M.Sci. Alfred Hospital and Monash University, Melbourne, VIC 3004, Australia (P.S.M.). p.myles@alfred.org.au

DOI: 10.1097/ALN.0000000000003977

References

- Myles PS, Myles DB, Galagher W, Chew C, MacDonald N, Dennis A: Minimal clinically important difference for three quality of recovery scales. Anesthesiology 2016; 125:39–45
- Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks P, Tugwell P: Minimal clinically important differences: Review of methods. J Rheumatol 2001; 28:406–12
- 3. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003; 41:582–92
- Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57:898–910
- Tashjian R.Z., Deloach J, Porucznik CA, Powell AP: Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. J Shoulder Elbow Surg 2009; 18:927–32
- Auffinger B, Lam S, Shen J, Roitberg BZ: Measuring surgical outcomes in subaxial degenerative cervical spine disease patients: Minimum clinically important difference as

- a tool for determining meaningful clinical improvement. Neurosurgery 2014; 74:206–13; discussion 213–4
- 7. Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, Martinelli F, Reeve BB, Gotay C, Greimel E, Flechtner H, Cleeland CS, Schmucker-Von Koch J, Weis J, Van Den Bent MJ, Stupp R, Taphoorn MJ, Bottomley A; EORTC PROBE Project and Brain Cancer Group: Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011; 22:2107–12
- 8. Corcoran TB, Myles PS, Forbes AB, Cheng AC, Bach LA, O'Loughlin E, Leslie K, Chan MTV, Story D, Short TG, Martin C, Coutts P, Ho KM; PADDI Investigators; Australian and New Zealand College of Anaesthetists Clinical Trials Network; Australasian Society for Infectious Diseases Clinical Research Network: Dexamethasone and surgical-site infection. N Engl J Med 2021; 384:1731–41
- Stark PA, Myles PS, Burke JA: Development and psychometric evaluation of a postoperative quality of recovery score: The QoR-15. Anesthesiology 2013; 118:1332-40
- Demumieux F, Ludes PO, Diemunsch P, Bennett-Guerrero E, Lujic M, Lefebvre F, Noll E: Validation of the translated Quality of Recovery-15 questionnaire in a French-speaking population. Br J Anaesth 2020; 124:761-7
- 11. Parker SL, Adogwa O, Mendenhall SK, Shau DN, Anderson WN, Cheng JS, Devin CJ, McGirt MJ: Determination of minimum clinically important difference (MCID) in pain, disability, and quality of life after revision fusion for symptomatic pseudoarthrosis. Spine J 2012; 12:1122–8
- 12. Guidance for industry: patient-reported outcome measures: Use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 2006; 4:79
- 13. de Vet HC, Ostelo RW, Terwee CB, van der Roer N, Knol DL, Beckerman H, Boers M, Bouter LM: Minimally important change determined by a visual method integrating an anchor-based and a distribution-based approach. Qual Life Res 2007; 16:131–42
- 14. Youden WJ: Index for rating diagnostic tests. Cancer 1950; 3:32–5
- 15. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH: A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. J Orthop Sports Phys Ther 2011; 41:319–27

(Accepted for publication August 17, 2021. Published online first on September 20, 2021.)